CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,312,711 | -49.5% | 50,952 | -37.6% | 0.06% | -45.0% |
| Q2 2023 | $4,581,024 | +78.6% | 81,600 | +256.0% | 0.10% | +40.8% |
| Q3 2021 | $2,565,000 | -56.3% | 22,919 | -36.7% | 0.07% | -62.4% |
| Q2 2021 | $5,866,000 | +2615.7% | 36,234 | +1947.1% | 0.19% | +2262.5% |
| Q1 2021 | $216,000 | -80.0% | 1,770 | -92.3% | 0.01% | -91.8% |
| Q2 2019 | $1,079,000 | – | 22,905 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |